Vatseba T. Study of the association between antihyperglycemic therapy and cancer in patients with type 2 diabetes mellitus / T. Vatseba, L. Sokolova, V. Pushkarev, N. Koshel // Галиц. лікар. вісн. - 2020. - 27, № 3. - С. 43-47. - Бібліогр.: 23 назв. - англ.The objective of the research was to investigate the features and association of antihyperglycemic therapy and cancer in patients with type 2 diabetes mellitus. The study included the analysis of medical records of patients with type 2 diabetes meliitus who were diagnosed with cancer during 2012 - 2016. The obtained results were processed by statistical methods using the software packages Microsoft Excel and Statistika-12. The significance of differences between the frequency of using different treatment schemes was assessed by the Pearson's test (x<^>2). To determine the risk of predicted events, the odds ratio, the 95 % confidence interval, the positive and negative prognostic values were calculated. There were diagnosed 533 cases of cancer in patients with type 2 diabetes mellitus. The most common scheme of antihyperglycemic therapy prior to the detection of malignant diseases was a combination of metformin and sulfonylurea derivatives (35,65 %), as well as monotherapy with sulfonylurea derivatives (17,26 %) and metformin (11,28 %). Prior to diagnosing cancer in 396 (74,30 %) patients, antihyperglycemic therapy that included sulfonylurea dіrivіtes or insulin was used. Among obese patients 68,82 % used sulfonylureas and insulin as part of antidiabetic therapy before diagnosis of cancer. The connection between insulin therapy and the risk of cancer development in patients with type 2 diabetes mellitus was proved (the odds ratio = 2,35; the 95 % confidence interval (1,91 - 2,91); p << 0,001). Conclusions: prior to the detection of cancer in patients with type 2 diabetes meliitus, the combination therapy with metformin and sulfonylurea derivatives was most often used. The association between insulin therapy and the development of cancer in patients with type 2 diabetes mellitus was revealed. Cancer screening is advisable for patients with type 2 diabetes mellitus and obesity, who receive as a therapy sulfonylurea dіrivіtes and/or insulin. Індекс рубрикатора НБУВ: Р415.160.23-52 + Р56-52
Рубрики:
Шифр НБУВ: Ж69358 Пошук видання у каталогах НБУВ Повний текст Наукова періодика України Додаткова інформація про автора(ів) публікації: (cписок формується автоматично, до списку можуть бути включені персоналії з подібними іменами або однофамільці) Якщо, ви не знайшли інформацію про автора(ів) публікації, маєте бажання виправити або відобразити більш докладну інформацію про науковців України запрошуємо заповнити "Анкету науковця"
|